心肾综合征（cardiorenal syndrome, CRS）是由心脏或肾脏两脏器中任一个器官衰竭而引起另一器官发生衰竭，从而二脏器同时出现衰竭的一组临床综合征；研究表明，中医药对治疗心肾综合症的优势显著；通过选取60例符合心肾亏虚兼肝郁证候的CRS患者，随机分为治疗组和对照组，每组各30例。两组患者均接受常规西药治疗，而治疗组在此基础上加服通痹舒心颗粒。在研究期间，对两组患者在治疗前后进行临床疗效、左室射血分数（left ventricular ejection fraction, LVEF）、左室舒张末期内径（left ventricular end-diastolic diameter, LVDD）、胱抑素C（cystatin C, Cys-C）、血清肌酐（serum creatinine, Scr）、尿素氮（blood urea nitrogen, BUN）以及B型钠尿肽前体（B-type natriuretic peptide precursor, NT-proBNP）水平的监测与比较。与对照组相比，治疗组的Cys-C、NT-proBNP、Scr和BUN水平显著降低。此外，治疗组患者在心悸、胸闷气短、下肢浮肿、身寒肢冷等临床症状以及LVEF水平方面均有显著改善，存在显著性差异（P<0.05）。结果表明：通痹舒心颗粒能够有效降低CRS患者的Cys-C、NT-proBNP、Scr和BUN水平，并改善其临床症状及LVEF水平。可见该药物的临床疗效确切，对CRS的临床治疗具有积极意义，可明显改善心肾功能，减少远期病死率。

Cardiorenal syndrome (CRS) is a clinical syndrome characterized by the simultaneous failure of both the heart and kidneys, with one organ's failure leading to the failure of the other. Increasing evidence suggests that traditional Chinese medicine(TCM) has increasingly significant advantages in treating CRS. 60 patients with CRS who met the criteria for both heart-kidney deficiency and liver depression were selected and randomly divided into a treatment group and a control group, with 30 patients in each group. Both groups received conventional western medical treatment, while the treatment group additionally took the Tongbi Shuxin Granules. During the study period, the clinical efficacy, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVDD), cystatin C (Cys-C), serum creatinine (Scr), blood urea nitrogen (BUN), and B-type natriuretic peptide precursor (NT-proBNP) levels were monitored and compared between the two groups before and after treatment. Compared with the control group, the treatment group shows significant reductions in Cys-C, NT-proBNP, Scr, and BUN levels. Furthermore, patients in the treatment group experience significant improvements in clinical symptoms such as palpitations, chest tightness, shortness of breath, lower limb edema, feelling cold, and cold limbs, as well as in LVEF levels, with significant differences (P < 0.05). The results indicate that the Tongbi Shuxin Granules can effectively reduce the levels of Cys-C, NT-proBNP, Scr, and BUN in CRS patients and improve their clinical symptoms and LVEF levels. Thus, the clinical efficacy of this medication is confirmed, and it has positive implications for the clinical treatment of CRS, significantly improving heart and kidney function and Reducing long-term survival rates.